文献速递头颈部肿瘤放疗

保留腮腺浅叶的调强放疗对鼻咽癌患者口干症的影响:一项前瞻性II期随机对照研究

Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.
PubMed 文献 · Radiother Oncol · 2022-07-08

该前瞻性II期随机对照研究将90例鼻咽癌患者随机分配至保留腮腺浅叶的调强放疗(SPLS-IMRT)组或常规调强放疗(C-IMRT)组,82例纳入口干症分析。SPLS-IMRT组放疗后12个月口干症发生率显著低于C-IMRT组(83.4% vs 95.0%,P=0.007),且3级口干症发生率更低(0% vs 12.5%,P<0.001),唾液流率更高,生存结局无显著差异。作者认为SPLS-IMRT通过更早恢复腮腺功能显著减少口干症且不损害生存,需开展III期临床试验。

要点

  • SPLS-IMRT组放疗后12个月口干症发生率为83.4%,显著低于C-IMRT组的95.0%(P=0.007)。
  • SPLS-IMRT组3级口干症发生率为0%,C-IMRT组为12.5%(P<0.001)。
  • 两组3年LRRFS、DMFS、OS均无显著差异(均P>0.05)。

核心结论

  • SPLS-IMRT通过比C-IMRT更早恢复腮腺功能,显著降低鼻咽癌患者放疗后12个月口干症发生率,且不损害生存。
  • 作者认为需开展III期临床试验。

研究设计与样本

  • 前瞻性II期随机对照研究,纳入90例组织学确诊且符合入组标准的鼻咽癌患者,随机分配接受SPLS-IMRT或C-IMRT。
  • 主要终点为放疗后12个月口干症发生率;次要终点包括口干症问卷(XQ)评分、非刺激唾液流率(USFR)、刺激唾液流率(SSFR)和生存结局。
  • 82例患者纳入口干症分析(SPLS-IMRT组42例,C-IMRT组40例)。

主要发现

  • 放疗后12个月,SPLS-IMRT组口干症发生率显著低于C-IMRT组(83.4% vs 95.0%,P=0.007),3级口干症发生率亦显著更低(0% vs 12.5%,P<0.001)。
  • 两组XQ评分中位变化相似(11.9分 vs 14.1分,P=0.194)。
  • SPLS-IMRT组中位USFR分数(0.67 vs 0.35,P=0.024)和中位SSFR分数(0.66 vs 0.32,P=0.021)均显著高于C-IMRT组。
  • SPLS-IMRT组与C-IMRT组的3年LRRFS、DMFS和OS分别为92.5% vs 90.9%、83.8% vs 81.7%、88.9% vs 88.2%(均P>0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需开展III期临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the incidence of xerostomia in nasopharyngeal carcinoma (NPC) patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT) and conventional IMRT (C-IMRT). METHODS: Patients with histologically confirmed NPC who met the eligibility criteria were randomly assigned to receive either SPLS-IMRT or C-IMRT. The primary endpoint was the incidence of xerostomia at 12 months post-IMRT. The secondary endpoints included the xerostomia questionnaire (XQ) score, unstimulated salivary flow rate (USFR), stimulated salivary flow rate (SSFR), and survival outcomes. RESULTS: Ninety patients were enrolled. Eighty-two patients were included for xerostomia analysis (42 in the SPLS-IMRT group and 40 in the C-IMRT group). At 12 months post-IMRT, the incidence of xerostomia in the SPLS-IMRT group was significantly lower than that in the C-IMRT group (83.4% vs 95.0%; P = 0.007), especially the grade 3 xerostomia (0% vs 12.5%; P < 0.001). The median change in XQ score was similar between the two groups (11.9 points vs 14.1 points; P = 0.194). There was a significantly higher median fractional USFR (0.67 vs 0.35; P = 0.024) and SSFR (0.66 vs 0.32; P = 0.021) in the SPLS-IMRT group than the C-IMRT group. The 3-year LRRFS, DMFS, and OS in the SPLS-IMRT and C-IMRT groups were 92.5% vs 90.9%, 83.8% vs 81.7%, and 88.9% vs 88.2% (all P > 0.05). CONCLUSION: SPLS-IMRT significantly reduced the incidence of xerostomia at 12 months post-IMRT in NPC by recovering parotid gland function earlier than C-IMRT, without compromising survivals. Phase III clinical trials are warranted. (ClinicalTrials.gov, number NCT05020067).

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Huang H, Miao J, Xiao X, et al. Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study. Radiother Oncol. 2022. PMID: 35817320. doi:10.1016/j.radonc.2022.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。